A Prospective, Open Label, Randomized Phase II Trial of Weekly Docetaxel Versus Weekly Vinorelbine as First Line Chemotherapy in Patients With Androgen Independent Prostate Cancer
Michael Krainer, Sandra Tomek, Katarzyna Elandt, Peter Horak, Walter Albrecht, Michael Eisenmenger, Wolfgang Höltl, Paul Schramek, Walter Stackl, Christoph Zielinski, Jochen Reibenwein
The Journal of Urology
June 2007 (Vol. 177, Issue 6, Pages 2141-2145) Abstract |
Full Text |
Full-Text PDF (98 KB)
No abstract is available. To read the body of this article, please view the Full Text online.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
